{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T03:11:51Z","timestamp":1793502711320,"version":"4.5.0"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1007\/s40265-018-0902-x","type":"journal-article","created":{"date-parts":[[2018,4,18]],"date-time":"2018-04-18T09:03:04Z","timestamp":1524042184000},"page":"675-692","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":338,"title":["Ceftazidime-Avibactam: A Review in the Treatment of Serious Gram-Negative Bacterial Infections"],"prefix":"10.1007","volume":"78","author":[{"given":"Matt","family":"Shirley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,4,18]]},"reference":[{"key":"902_CR1","unstructured":"World Health Organization. Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics. 2017. http:\/\/www.who.int\/medicines\/publications\/WHO-PPL-Short_Summary_25Feb-ET_NM_WHO.pdf?ua=1. Accessed 16 Mar 2018."},{"issue":"5","key":"902_CR2","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1111\/joim.12342","volume":"277","author":"T T\u00e4ngd\u00e9n","year":"2015","unstructured":"T\u00e4ngd\u00e9n T, Giske CG. Global dissemination of extensively drug-resistant carbapenemase-producing Enterobacteriaceae: clinical perspectives on detection, treatment and infection control. J Intern Med. 2015;277(5):501\u201312.","journal-title":"J Intern Med"},{"issue":"10","key":"902_CR3","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1038\/nrurol.2015.199","volume":"12","author":"HM Zowawi","year":"2015","unstructured":"Zowawi HM, Harris PNA, Roberts MJ, et al. The emerging threat of multidrug-resistant Gram-negative bacteria in urology. Nat Rev Urol. 2015;12(10):570\u201384.","journal-title":"Nat Rev Urol."},{"issue":"3","key":"902_CR4","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1186\/cc8892","volume":"14","author":"K Bush","year":"2010","unstructured":"Bush K. Bench-to-bedside review: the role of \u03b2-lactamases in antibiotic-resistant Gram-negative infections. Crit Care. 2010;14(3):224.","journal-title":"Crit Care"},{"issue":"3","key":"902_CR5","doi-asserted-by":"publisher","first-page":"313","DOI":"10.2165\/11533040-000000000-00000","volume":"70","author":"JDD Pitout","year":"2010","unstructured":"Pitout JDD. Infections with extended-spectrum \u03b2-lactamase-producing Enterobacteriaceae: changing epidemiology and drug treatment choices. Drugs. 2010;70(3):313\u201333.","journal-title":"Drugs."},{"issue":"5","key":"902_CR6","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1111\/j.1469-0691.2012.03821.x","volume":"18","author":"R Cant\u00f3n","year":"2012","unstructured":"Cant\u00f3n R, Ak\u00f3va M, Carmeli Y, et al. Rapid evolution and spread of carbapenemases among Enterobacteriaceae in Europe. Clin Microbiol Infect. 2012;18(5):413\u201331.","journal-title":"Clin Microbiol Infect"},{"issue":"6","key":"902_CR7","doi-asserted-by":"publisher","first-page":"651","DOI":"10.2165\/11318430-000000000-00000","volume":"70","author":"C Bebrone","year":"2010","unstructured":"Bebrone C, Lassaux P, Vercheval L, et al. Current challenges in antimicrobial chemotherapy: focus on \u03b2-lactamase inhibition. Drugs. 2010;70(6):651\u201379.","journal-title":"Drugs."},{"issue":"2","key":"902_CR8","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1093\/jac\/dkh358","volume":"54","author":"A Bonnefoy","year":"2004","unstructured":"Bonnefoy A, Dupuis-Hamelin C, Steier V, et al. In vitro activity of AVE1330A, an innovative broad-spectrum non-\u03b2-lactam \u03b2-lactamase inhibitor. J Antimicrob Chemother. 2004;54(2):410\u20137.","journal-title":"J Antimicrob Chemother"},{"issue":"29","key":"902_CR9","doi-asserted-by":"publisher","first-page":"11663","DOI":"10.1073\/pnas.1205073109","volume":"109","author":"DE Ehmann","year":"2012","unstructured":"Ehmann DE, Jahi\u0107 H, Ross PL, et al. Avibactam is a covalent, reversible, non-\u03b2-lactam \u03b2-lactamase inhibitor. Proc Natl Acad Sci USA. 2012;109(29):11663\u20138.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"12","key":"902_CR10","doi-asserted-by":"publisher","first-page":"5132","DOI":"10.1128\/AAC.00568-10","volume":"54","author":"T Stachyra","year":"2010","unstructured":"Stachyra T, P\u00e9chereau M-C, Bruneau J-M, et al. Mechanistic studies of the inactivation of TEM-1 and P99 by NXL104, a novel non-\u03b2-lactam \u03b2-lactamase inhibitor. Antimicrob Agents Chemother. 2010;54(12):5132\u20138.","journal-title":"Antimicrob Agents Chemother"},{"key":"902_CR11","unstructured":"European Medicines Agency. European public assessment report: Zavicefta (ceftazidime\/avibactam). 2016. http:\/\/www.ema.europa.eu. Accessed 16 Mar 2018."},{"issue":"2","key":"902_CR12","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1128\/AAC.04146-14","volume":"59","author":"J Berkhout","year":"2015","unstructured":"Berkhout J, Melchers MJ, van Mil AC, et al. In vitro activity of ceftazidime-avibactam combination in in vitro checkerboard assays. Antimicrob Agents Chemother. 2015;59(2):1138\u201344.","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"902_CR13","doi-asserted-by":"publisher","first-page":"2434","DOI":"10.1128\/AAC.01722-10","volume":"55","author":"PRS Lagac\u00e9-Wiens","year":"2011","unstructured":"Lagac\u00e9-Wiens PRS, Tailor F, Simner P, et al. Activity of NXL104 in combination with \u03b2-lactams against genetically characterized Escherichia coli and Klebsiella pneumoniae isolates producing class A extended-spectrum \u03b2-lactamases and class C \u03b2-lactamases. Antimicrob Agents Chemother. 2011;55(5):2434\u20137.","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"902_CR14","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1128\/AAC.04218-14","volume":"59","author":"P Levasseur","year":"2015","unstructured":"Levasseur P, Girard A-M, Miossec C, et al. In vitro antibacterial activity of the ceftazidime-avibactam combination against Enterobacteriaceae, including strains with well-characterized \u03b2-lactamases. Antimicrob Agents Chemother. 2015;59(4):1931\u20134.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"902_CR15","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1128\/AAC.00756-10","volume":"55","author":"DM Livermore","year":"2011","unstructured":"Livermore DM, Mushtaq S, Warner M, et al. Activities of NXL104 combinations with ceftazidime and aztreonam against carbapenemase-producing Enterobacteriaceae. Antimicrob Agents Chemother. 2011;55(1):390\u20134.","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"902_CR16","doi-asserted-by":"publisher","first-page":"2849","DOI":"10.1128\/AAC.02286-15","volume":"60","author":"JA Karlowsky","year":"2016","unstructured":"Karlowsky JA, Biedenbach DJ, Kazmierczak KM, et al. Activity of ceftazidime-avibactam against extended-spectrum- and AmpC \u03b2-lactamase-producing Enterobacteriaceae collected in the INFORM global surveillance study from 2012 to 2014. Antimicrob Agents Chemother. 2016;60(5):2849\u201357.","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"902_CR17","doi-asserted-by":"publisher","first-page":"4490","DOI":"10.1128\/AAC.00107-16","volume":"60","author":"KM Kazmierczak","year":"2016","unstructured":"Kazmierczak KM, Biedenbach DJ, Hackel M, et al. Global dissemination of bla\n                           KPC into bacterial species beyond Klebsiella pneumoniae and in vitro susceptibility to ceftazidime-avibactam and aztreonam-avibactam. Antimicrob Agents Chemother. 2016;60(8):4490\u2013500.","journal-title":"Antimicrob Agents Chemother"},{"key":"902_CR18","unstructured":"European Medicines Agency. Zavicefta: summary of product characteristics. 2018. http:\/\/www.ema.europa.eu. Accessed 16 Mar 2018."},{"key":"902_CR19","unstructured":"US FDA. Avycaz (ceftazidime and avibactam) for injection, for intravenous use: US prescribing information. 2018. https:\/\/www.accessdata.fda.gov. Accessed 16 Mar 2018."},{"issue":"4","key":"902_CR20","doi-asserted-by":"publisher","first-page":"577","DOI":"10.2165\/00003495-199549040-00008","volume":"49","author":"CP Rains","year":"1995","unstructured":"Rains CP, Bryson HM, Peters DH. Ceftazidime: an update of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy. Drugs. 1995;49(4):577\u2013617.","journal-title":"Drugs."},{"issue":"6","key":"902_CR21","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.1128\/AAC.02247-12","volume":"57","author":"SD Lahiri","year":"2013","unstructured":"Lahiri SD, Mangani S, Durand-Reville T, et al. Structural insight into potent broad-spectrum inhibition with reversible recyclization mechanism: avibactam in complex with CTX-M-15 and Pseudomonas aeruginosa AmpC \u03b2-lactamases. Antimicrob Agents Chemother. 2013;57(6):2496\u2013505.","journal-title":"Antimicrob Agents Chemother"},{"issue":"39","key":"902_CR22","doi-asserted-by":"publisher","first-page":"27960","DOI":"10.1074\/jbc.M113.485979","volume":"288","author":"DE Ehmann","year":"2013","unstructured":"Ehmann DE, Jahi\u0107 H, Ross PL, et al. Kinetics of avibactam inhibition against class A, C, and D \u03b2-lactamases. J Biol Chem. 2013;288(39):27960\u201371.","journal-title":"J Biol Chem"},{"issue":"1","key":"902_CR23","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.diagmicrobio.2015.02.003","volume":"82","author":"KM Papp-Wallace","year":"2015","unstructured":"Papp-Wallace KM, Bajaksouzian S, Abdelhamed AM, et al. Activities of ceftazidime, ceftaroline, and aztreonam alone and combined with avibactam against isogenic Escherichia coli strains expressing selected single \u03b2-lactamases. Diagn Microbiol Infect Dis. 2015;82(1):65\u20139.","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"1","key":"902_CR24","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.ijantimicag.2011.09.012","volume":"39","author":"Z Akta\u015f","year":"2012","unstructured":"Akta\u015f Z, Kayacan C, Oncul O. In vitro activity of avibactam (NXL104) in combination with \u03b2-lactams against Gram-negative bacteria, including OXA-48 \u03b2-lactamase-producing Klebsiella pneumoniae. Int J Antimicrob Agents. 2012;39(1):86\u20139.","journal-title":"Int J Antimicrob Agents"},{"issue":"5","key":"902_CR25","doi-asserted-by":"publisher","first-page":"3163","DOI":"10.1128\/AAC.03042-15","volume":"60","author":"BLM de Jonge","year":"2016","unstructured":"de Jonge BLM, Karlowsky JA, Kazmierczak KM, et al. In vitro susceptibility to ceftazidime-avibactam of carbapenem-nonsusceptible Enterobacteriaceae isolates collected during the INFORM global surveillance study (2012 to 2014). Antimicrob Agents Chemother. 2016;60(5):3163\u20139.","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"902_CR26","doi-asserted-by":"publisher","first-page":"4743","DOI":"10.1128\/AAC.00220-16","volume":"60","author":"WW Nichols","year":"2016","unstructured":"Nichols WW, de Jonge BLM, Kazmierczak KM, et al. In vitro susceptibility of global surveillance isolates of Pseudomonas aeruginosa to ceftazidime-avibactam (INFORM 2012 to 2014). Antimicrob Agents Chemother. 2016;60(8):4743\u20139.","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"902_CR27","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.ijantimicag.2014.12.033","volume":"45","author":"R Testa","year":"2015","unstructured":"Testa R, Cant\u00f3n R, Giani T, et al. In vitro activity of ceftazidime, ceftaroline and aztreonam alone and in combination with avibactam against European Gram-negative and Gram-positive clinical isolates. Int J Antimicrob Agents. 2015;45(6):641\u20136.","journal-title":"Int J Antimicrob Agents"},{"issue":"5","key":"902_CR28","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1128\/AAC.02969-15","volume":"60","author":"DJ Buehrle","year":"2016","unstructured":"Buehrle DJ, Shields RK, Chen L, et al. Evaluation of the in vitro activity of ceftazidime-avibactam and ceftolozane-tazobactam against meropenem-resistant Pseudomonas aeruginosa isolates. Antimicrob Agents Chemother. 2016;60(5):3227\u201331.","journal-title":"Antimicrob Agents Chemother"},{"key":"902_CR29","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.ijid.2017.06.007","volume":"62","author":"A Alatoom","year":"2017","unstructured":"Alatoom A, Elsayed H, Lawlor K, et al. Comparison of antimicrobial activity between ceftolozane-tazobactam and ceftazidime-avibactam against multidrug-resistant isolates of Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa. Int J Infect Dis. 2017;62:39\u201343.","journal-title":"Int J Infect Dis."},{"issue":"2","key":"902_CR30","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s40265-015-0524-5","volume":"76","author":"LJ Scott","year":"2016","unstructured":"Scott LJ. Ceftolozane\/tazobactam: a review in complicated intra-abdominal and urinary tract infections. Drugs. 2016;76(2):231\u201342.","journal-title":"Drugs."},{"issue":"12","key":"902_CR31","doi-asserted-by":"publisher","first-page":"6137","DOI":"10.1128\/AAC.00851-12","volume":"56","author":"JL Crandon","year":"2012","unstructured":"Crandon JL, Schuck VJ, Banevicius MA, et al. Comparative in vitro and in vivo efficacies of human simulated doses of ceftazidime and ceftazidime-avibactam against Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2012;56(12):6137\u201346.","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"902_CR32","doi-asserted-by":"publisher","first-page":"6913","DOI":"10.1128\/AAC.03267-14","volume":"58","author":"SH MacVane","year":"2014","unstructured":"MacVane SH, Crandon JL, Nichols WW, et al. In vivo efficacy of humanized exposures of ceftazidime-avibactam in comparison with ceftazidime against contemporary Enterobacteriaceae isolates. Antimicrob Agents Chemother. 2014;58(11):6913\u20139.","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"902_CR33","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1128\/AAC.02161-13","volume":"58","author":"ST Housman","year":"2014","unstructured":"Housman ST, Crandon JL, Nichols WW, et al. Efficacies of ceftazidime-avibactam and ceftazidime against Pseudomonas aeruginosa in a murine lung infection model. Antimicrob Agents Chemother. 2014;58(3):1365\u201371.","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"902_CR34","doi-asserted-by":"publisher","first-page":"6490","DOI":"10.1128\/AAC.03579-14","volume":"58","author":"P Levasseur","year":"2014","unstructured":"Levasseur P, Girard A-M, Lavallade L, et al. Efficacy of a ceftazidime-avibactam combination in a murine model of septicemia caused by Enterobacteriaceae species producing AmpC or extended-spectrum \u03b2-lactamases. Antimicrob Agents Chemother. 2014;58(11):6490\u20135.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"902_CR35","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1128\/AAC.01198-10","volume":"55","author":"A Endimiani","year":"2011","unstructured":"Endimiani A, Hujer KM, Hujer AM, et al. Evaluation of ceftazidime and NXL104 in two murine models of infection due to KPC-producing Klebsiella pneumoniae. Antimicrob Agents Chemother. 2011;55(1):82\u20135.","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"902_CR36","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1093\/jac\/dkv004","volume":"70","author":"SD Lahiri","year":"2015","unstructured":"Lahiri SD, Walkup GK, Whiteaker JD, et al. Selection and molecular characterization of ceftazidime\/avibactam-resistant mutants in Pseudomonas aeruginosa strains containing derepressed AmpC. J Antimicrob Chemother. 2015;70(6):1650\u20138.","journal-title":"J Antimicrob Chemother"},{"issue":"6","key":"902_CR37","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1093\/jac\/dks079","volume":"67","author":"DM Livermore","year":"2012","unstructured":"Livermore DM, Mushtaq S, Barker K, et al. Characterization of \u03b2-lactamase and porin mutants of Enterobacteriaceae selected with ceftaroline\u2009+\u2009avibactam (NXL104). J Antimicrob Chemother. 2012;67(6):1354\u20138.","journal-title":"J Antimicrob Chemother"},{"issue":"9","key":"902_CR38","doi-asserted-by":"publisher","first-page":"5324","DOI":"10.1128\/AAC.00678-15","volume":"59","author":"DM Livermore","year":"2015","unstructured":"Livermore DM, Warner M, Jamrozy D, et al. In vitro selection of ceftazidime-avibactam resistance in Enterobacteriaceae with KPC-3 carbapenemase. Antimicrob Agents Chemother. 2015;59(9):5324\u201330.","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"902_CR39","doi-asserted-by":"publisher","first-page":"e02534-16","DOI":"10.1128\/AAC.02534-16","volume":"61","author":"G Haidar","year":"2017","unstructured":"Haidar G, Clancy CJ, Shields RK, et al. Mutations in bla\n                           KPC-3 that confer ceftazidime-avibactam resistance encode novel KPC-3 variants that function as extended-spectrum \u03b2-lactamases. Antimicrob Agents Chemother. 2017;61(5):e02534-16.","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"902_CR40","doi-asserted-by":"publisher","first-page":"e02097-16","DOI":"10.1128\/AAC.02097-16","volume":"61","author":"RK Shields","year":"2017","unstructured":"Shields RK, Chen L, Cheng S, et al. Emergence of ceftazidime-avibactam resistance due to plasmid-borne bla\n                           KPC-3 mutations during treatment of carbapenem-resistant Klebsiella pneumoniae infections. Antimicrob Agents Chemother. 2017;61(3):e02097-16.","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"902_CR41","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1128\/AAC.04238-14","volume":"59","author":"ML Winkler","year":"2015","unstructured":"Winkler ML, Papp-Wallace KM, Hujer AM, et al. Unexpected challenges in treating multidrug-resistant Gram-negative bacteria: resistance to ceftazidime-avibactam in archived isolates of Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2015;59(2):1020\u20139.","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"902_CR42","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1128\/AAC.01585-15","volume":"60","author":"J-M Pag\u00e8s","year":"2016","unstructured":"Pag\u00e8s J-M, Peslier S, Keating TA, et al. Role of the outer membrane and porins in susceptibility of \u03b2-lactamase-producing Enterobacteriaceae to ceftazidime-avibactam. Antimicrob Agents Chemother. 2016;60(3):1349\u201359.","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"902_CR43","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1093\/jac\/dkx066","volume":"72","author":"Z Shen","year":"2017","unstructured":"Shen Z, Ding B, Ye M, et al. High ceftazidime hydrolysis activity and porin OmpK35 deficiency contribute to the decreased susceptibility to ceftazidime\/avibactam in KPC-producing Klebsiella pneumoniae. J Antimicrob Chemother. 2017;72(7):1930\u20136.","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"902_CR44","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1093\/jac\/dks468","volume":"68","author":"AE Muller","year":"2013","unstructured":"Muller AE, Punt N, Mouton JW. Optimal exposures of ceftazidime predict the probability of microbiological and clinical outcome in the treatment of nosocomial pneumonia. J Antimicrob Chemother. 2013;68(4):900\u20136.","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"902_CR45","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1128\/AAC.01269-15","volume":"60","author":"J Berkhout","year":"2016","unstructured":"Berkhout J, Melchers MJ, van Mil AC, et al. Pharmacodynamics of ceftazidime and avibactam in neutropenic mice with thigh or lung infection. Antimicrob Agents Chemother. 2016;60(1):368\u201375.","journal-title":"Antimicrob Agents Chemother"},{"key":"902_CR46","unstructured":"Li J, Zhou D, Nichols WW, et al. PK\/PD target attainment analyses and assessment of dose adjustments for renal insufficiency for ceftazidime-avibactam (CAZ-AVI) in patients with complicated intra-abdominal infection (cIAI), complicated urinary tract infection (cUTI) or nosocomial pneumonia (NP) [abstract no. R6302]. In: American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition. 2015."},{"issue":"5","key":"902_CR47","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s40261-015-0283-9","volume":"35","author":"H Merdjan","year":"2015","unstructured":"Merdjan H, Rangaraju M, Tarral A. Safety and pharmacokinetics of single and multiple ascending doses of avibactam alone and in combination with ceftazidime in healthy male volunteers: results of two randomized, placebo-controlled studies. Clin Drug Investig. 2015;35(5):307\u201317.","journal-title":"Clin Drug Investig."},{"issue":"5","key":"902_CR48","doi-asserted-by":"publisher","first-page":"e00172","DOI":"10.1002\/prp2.172","volume":"3","author":"S Das","year":"2015","unstructured":"Das S, Li J, Armstrong J, et al. Randomized pharmacokinetic and drug-drug interaction studies of ceftazidime, avibactam, and metronidazole in healthy subjects. Pharmacol Res Perspect. 2015;3(5):e00172.","journal-title":"Pharmacol Res Perspect."},{"issue":"10","key":"902_CR49","doi-asserted-by":"publisher","first-page":"2862","DOI":"10.1093\/jac\/dkv170","volume":"70","author":"DP Nicolau","year":"2015","unstructured":"Nicolau DP, Siew L, Armstrong J, et al. Phase 1 study assessing the steady-state concentration of ceftazidime and avibactam in plasma and epithelial lining fluid following two dosing regimens. J Antimicrob Chemother. 2015;70(10):2862\u20139.","journal-title":"J Antimicrob Chemother"},{"key":"902_CR50","unstructured":"Dimelow R, Wright J, Macpherson M, et al. Population pharmacokinetic modelling of ceftazidime and avibactam in the plasma and epithelial lining fluid of healthy volunteers [abstract and poster no. EP0350]. In: 27th European Congress of Clinical Microbiology and Infectious Diseases. 2017."},{"issue":"5","key":"902_CR51","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1124\/dmd.113.055335","volume":"42","author":"K Vishwanathan","year":"2014","unstructured":"Vishwanathan K, Mair S, Gupta A, et al. Assessment of the mass balance recovery and metabolite profile of avibactam in humans and in vitro drug-drug interaction potential. Drug Metab Dispos. 2014;42(5):932\u201342.","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"902_CR52","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1128\/AAC.25.2.201","volume":"25","author":"LS Welage","year":"1984","unstructured":"Welage LS, Schultz RW, Schentag JJ. Pharmacokinetics of ceftazidime in patients with renal insufficiency. Antimicrob Agents Chemother. 1984;25(2):201\u20134.","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"902_CR53","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1002\/jcph.793","volume":"57","author":"H Merdjan","year":"2017","unstructured":"Merdjan H, Tarral A, Das S, et al. Phase 1 study assessing the pharmacokinetic profile and safety of avibactam in patients with renal impairment. J Clin Pharmacol. 2017;57(2):211\u20138.","journal-title":"J Clin Pharmacol"},{"issue":"4","key":"902_CR54","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/j.clinthera.2015.01.009","volume":"37","author":"A Tarral","year":"2015","unstructured":"Tarral A, Merdjan H. Effect of age and sex on the pharmacokinetics and safety of avibactam in healthy volunteers. Clin Ther. 2015;37(4):877\u201386.","journal-title":"Clin Ther"},{"issue":"6","key":"902_CR55","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1093\/cid\/ciw378","volume":"63","author":"FM Wagenlehner","year":"2016","unstructured":"Wagenlehner FM, Sobel JD, Newell P, et al. Ceftazidime-avibactam versus doripenem for the treatment of complicated urinary tract infections, including acute pyelonephritis: RECAPTURE, a phase 3 randomized trial program. Clin Infect Dis. 2016;63(6):754\u201362.","journal-title":"Clin Infect Dis"},{"issue":"6","key":"902_CR56","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/S1473-3099(16)30004-4","volume":"16","author":"Y Carmeli","year":"2016","unstructured":"Carmeli Y, Armstrong J, Laud PJ, et al. Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study. Lancet Infect Dis. 2016;16(6):661\u201373.","journal-title":"Lancet Infect Dis."},{"issue":"11","key":"902_CR57","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1093\/cid\/ciw133","volume":"62","author":"JE Mazuski","year":"2016","unstructured":"Mazuski JE, Gasink LB, Armstrong J, et al. Efficacy and safety of ceftazidime-avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infection: results from a randomized, controlled, double-blind, phase 3 program. Clin Infect Dis. 2016;62(11):1380\u20139.","journal-title":"Clin Infect Dis"},{"issue":"5","key":"902_CR58","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.ijantimicag.2017.01.010","volume":"49","author":"X Qin","year":"2017","unstructured":"Qin X, Tran BG, Kim MJ, et al. A randomised, double-blind, phase 3 study comparing the efficacy and safety of ceftazidime\/avibactam plus metronidazole versus meropenem for complicated intra-abdominal infections in hospitalised adults in Asia. Int J Antimicrob Agents. 2017;49(5):579\u201388.","journal-title":"Int J Antimicrob Agents"},{"issue":"3","key":"902_CR59","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/S1473-3099(17)30747-8","volume":"18","author":"A Torres","year":"2017","unstructured":"Torres A, Zhong N, Pachl J, et al. Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial. Lancet Infect Dis. 2017;18(3):285\u201395.","journal-title":"Lancet Infect Dis."},{"key":"902_CR60","doi-asserted-by":"crossref","unstructured":"Stone GG, Gasink L, Newell P, et al. Efficacy of ceftazidime-avibactam against multi-drug resistant Enterobacteriaceae and Pseudomonas aeruginosa from the phase 3 clinical trial program [abstract no. 2044 plus poster]. In: IDWeek. 2016.","DOI":"10.1093\/ofid\/ofw172.1592"},{"key":"902_CR61","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1186\/s12879-015-1054-1","volume":"15","author":"Y Golan","year":"2015","unstructured":"Golan Y. Empiric therapy for hospital-acquired, Gram-negative complicated intra-abdominal infection and complicated urinary tract infections: a systematic literature review of current and emerging treatment options. BMC Infect Dis. 2015;15:313.","journal-title":"BMC Infect Dis"},{"key":"902_CR62","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s13017-016-0089-y","volume":"11","author":"M Sartelli","year":"2016","unstructured":"Sartelli M, Weber DG, Rupp\u00e9 E, et al. Antimicrobials: a global alliance for optimizing their rational use in intra-abdominal infections (AGORA). World J Emerg Surg. 2016;11:33.","journal-title":"World J Emerg Surg."},{"issue":"5","key":"902_CR63","doi-asserted-by":"publisher","first-page":"e61","DOI":"10.1093\/cid\/ciw353","volume":"63","author":"AC Kalil","year":"2016","unstructured":"Kalil AC, Metersky ML, Klompas M, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis. 2016;63(5):e61\u2013111.","journal-title":"Clin Infect Dis"},{"key":"902_CR64","unstructured":"European Association of Urology. Urological infections guidelines. 2017. http:\/\/uroweb.org\/guideline\/urological-infections\/. Accessed 16 Mar 2018."},{"issue":"12","key":"902_CR65","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s11908-016-0552-7","volume":"18","author":"A Arizpe","year":"2016","unstructured":"Arizpe A, Reveles KR, Patel SD, et al. Updates in the management of cephalosporin-resistant Gram-negative bacteria. Curr Infect Dis Rep. 2016;18(12):39.","journal-title":"Curr Infect Dis Rep."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-018-0902-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-018-0902-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-018-0902-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T11:06:02Z","timestamp":1744715162000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-018-0902-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":65,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["902"],"URL":"https:\/\/doi.org\/10.1007\/s40265-018-0902-x","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"18 April 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Matt Shirley is a salaried employee of Adis\/Springer, is responsible for the article content and declares no relevant conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}